 Kavita Nair
Concepts (213)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 7 | 2023 | 489 | 1.980 |
Why?
| | Insurance, Pharmaceutical Services | 6 | 2020 | 24 | 1.430 |
Why?
| | Managed Care Programs | 6 | 2014 | 140 | 1.340 |
Why?
| | Drugs, Generic | 3 | 2021 | 28 | 1.330 |
Why?
| | Chronic Disease | 6 | 2020 | 1808 | 0.970 |
Why?
| | Drug Compounding | 1 | 2026 | 107 | 0.910 |
Why?
| | Anti-Obesity Agents | 1 | 2026 | 67 | 0.910 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 3 | 2022 | 83 | 0.890 |
Why?
| | Prescription Drugs | 2 | 2021 | 111 | 0.880 |
Why?
| | Glucagon-Like Peptides | 1 | 2026 | 71 | 0.860 |
Why?
| | Drug Costs | 2 | 2025 | 117 | 0.810 |
Why?
| | Health Resources | 2 | 2016 | 130 | 0.760 |
Why?
| | Choice Behavior | 2 | 2020 | 180 | 0.730 |
Why?
| | Cost Sharing | 3 | 2020 | 20 | 0.720 |
Why?
| | Insurance Benefits | 3 | 2010 | 12 | 0.690 |
Why?
| | Nervous System Diseases | 2 | 2023 | 286 | 0.690 |
Why?
| | Retinal Degeneration | 1 | 2021 | 40 | 0.660 |
Why?
| | Health Services | 2 | 2009 | 113 | 0.540 |
Why?
| | Health Expenditures | 5 | 2017 | 194 | 0.510 |
Why?
| | Medicare Part D | 2 | 2021 | 23 | 0.490 |
Why?
| | Hypertension | 2 | 2014 | 1273 | 0.450 |
Why?
| | Chlorthalidone | 1 | 2014 | 3 | 0.440 |
Why?
| | Hydrochlorothiazide | 1 | 2014 | 7 | 0.440 |
Why?
| | Insurance Coverage | 2 | 2011 | 244 | 0.440 |
Why?
| | Hospital Costs | 1 | 2016 | 125 | 0.440 |
Why?
| | Patient Admission | 1 | 2016 | 220 | 0.400 |
Why?
| | Practice Patterns, Physicians' | 2 | 2021 | 1371 | 0.390 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2013 | 38 | 0.390 |
Why?
| | Tetrazoles | 1 | 2013 | 50 | 0.390 |
Why?
| | Insurance, Health | 3 | 2016 | 310 | 0.390 |
Why?
| | Immunologic Factors | 2 | 2015 | 260 | 0.380 |
Why?
| | Antihypertensive Agents | 2 | 2014 | 519 | 0.370 |
Why?
| | Arthritis, Gouty | 1 | 2012 | 13 | 0.370 |
Why?
| | Fibric Acids | 1 | 2012 | 2 | 0.370 |
Why?
| | Gout Suppressants | 1 | 2012 | 19 | 0.370 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2012 | 345 | 0.370 |
Why?
| | Acute Coronary Syndrome | 1 | 2016 | 297 | 0.360 |
Why?
| | Imidazoles | 1 | 2013 | 247 | 0.360 |
Why?
| | Drug Labeling | 1 | 2012 | 37 | 0.360 |
Why?
| | Absenteeism | 1 | 2012 | 52 | 0.360 |
Why?
| | Medicare | 3 | 2025 | 903 | 0.360 |
Why?
| | Off-Label Use | 1 | 2012 | 51 | 0.350 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2025 | 992 | 0.350 |
Why?
| | Health Care Costs | 2 | 2012 | 425 | 0.340 |
Why?
| | Inpatients | 1 | 2016 | 553 | 0.340 |
Why?
| | Hospital Mortality | 1 | 2016 | 1038 | 0.330 |
Why?
| | United States | 15 | 2025 | 16098 | 0.330 |
Why?
| | Diagnostic Tests, Routine | 1 | 2011 | 107 | 0.310 |
Why?
| | Blood Pressure | 2 | 2014 | 1779 | 0.310 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2012 | 443 | 0.310 |
Why?
| | Retrospective Studies | 15 | 2024 | 17291 | 0.300 |
Why?
| | Health Benefit Plans, Employee | 1 | 2009 | 25 | 0.290 |
Why?
| | Adrenal Cortex Hormones | 1 | 2012 | 484 | 0.290 |
Why?
| | Humans | 37 | 2026 | 145474 | 0.290 |
Why?
| | Dyslipidemias | 2 | 2012 | 184 | 0.280 |
Why?
| | Antibodies, Monoclonal | 3 | 2012 | 1505 | 0.280 |
Why?
| | Middle Aged | 19 | 2024 | 36215 | 0.280 |
Why?
| | Program Development | 1 | 2010 | 368 | 0.270 |
Why?
| | Autoimmune Diseases | 1 | 2012 | 468 | 0.270 |
Why?
| | Loratadine | 2 | 2005 | 2 | 0.260 |
Why?
| | Negotiating | 2 | 2025 | 34 | 0.250 |
Why?
| | Male | 24 | 2025 | 72842 | 0.250 |
Why?
| | Diabetes Mellitus | 3 | 2017 | 1097 | 0.250 |
Why?
| | Nonprescription Drugs | 2 | 2005 | 69 | 0.250 |
Why?
| | Oklahoma | 1 | 2026 | 22 | 0.240 |
Why?
| | Female | 24 | 2025 | 78844 | 0.240 |
Why?
| | Antirheumatic Agents | 1 | 2009 | 307 | 0.230 |
Why?
| | Adult | 17 | 2024 | 40777 | 0.230 |
Why?
| | Models, Economic | 2 | 2016 | 61 | 0.220 |
Why?
| | Stiff-Person Syndrome | 1 | 2024 | 14 | 0.220 |
Why?
| | Drug Prescriptions | 3 | 2005 | 288 | 0.220 |
Why?
| | Lupus Vasculitis, Central Nervous System | 1 | 2024 | 14 | 0.210 |
Why?
| | Infusions, Intravenous | 2 | 2023 | 428 | 0.210 |
Why?
| | Aquaporin 4 | 1 | 2024 | 101 | 0.210 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2024 | 122 | 0.200 |
Why?
| | Neurofilament Proteins | 1 | 2024 | 79 | 0.200 |
Why?
| | Aged | 15 | 2025 | 26153 | 0.200 |
Why?
| | Insurance Claim Review | 3 | 2017 | 83 | 0.200 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2014 | 2028 | 0.200 |
Why?
| | Natalizumab | 2 | 2015 | 41 | 0.190 |
Why?
| | Neurology | 2 | 2023 | 116 | 0.190 |
Why?
| | Prescription Fees | 1 | 2003 | 4 | 0.190 |
Why?
| | Quality Indicators, Health Care | 1 | 2005 | 336 | 0.190 |
Why?
| | Neuromyelitis Optica | 1 | 2024 | 140 | 0.190 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2025 | 198 | 0.190 |
Why?
| | Patient Outcome Assessment | 1 | 2023 | 130 | 0.180 |
Why?
| | Metabolic Networks and Pathways | 1 | 2022 | 174 | 0.180 |
Why?
| | Information Services | 1 | 2001 | 43 | 0.170 |
Why?
| | Cost-Benefit Analysis | 5 | 2025 | 639 | 0.170 |
Why?
| | Myeloid Cells | 1 | 2022 | 147 | 0.170 |
Why?
| | Young Adult | 8 | 2024 | 14218 | 0.170 |
Why?
| | Neurologists | 1 | 2021 | 23 | 0.170 |
Why?
| | Community Participation | 1 | 2001 | 123 | 0.160 |
Why?
| | Atrophy | 1 | 2021 | 199 | 0.160 |
Why?
| | Infliximab | 2 | 2012 | 111 | 0.160 |
Why?
| | Rituximab | 1 | 2021 | 210 | 0.150 |
Why?
| | Attitude to Health | 1 | 2003 | 430 | 0.150 |
Why?
| | Arthritis, Rheumatoid | 1 | 2009 | 1180 | 0.150 |
Why?
| | Dementia | 1 | 2023 | 327 | 0.140 |
Why?
| | Patient Satisfaction | 1 | 2003 | 709 | 0.140 |
Why?
| | Cross-Sectional Studies | 3 | 2026 | 5904 | 0.140 |
Why?
| | Cohort Studies | 4 | 2013 | 6013 | 0.130 |
Why?
| | B-Lymphocytes | 1 | 2022 | 870 | 0.130 |
Why?
| | Pharmaceutical Services | 2 | 2011 | 76 | 0.120 |
Why?
| | Adolescent | 7 | 2024 | 22529 | 0.120 |
Why?
| | Drug Monitoring | 2 | 2010 | 401 | 0.120 |
Why?
| | Protein Kinase Inhibitors | 1 | 2022 | 981 | 0.120 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2025 | 1189 | 0.120 |
Why?
| | Models, Statistical | 1 | 2020 | 671 | 0.120 |
Why?
| | Drug Utilization Review | 3 | 2005 | 61 | 0.110 |
Why?
| | Aged, 80 and over | 5 | 2025 | 8333 | 0.110 |
Why?
| | Systole | 1 | 2014 | 181 | 0.100 |
Why?
| | Losartan | 1 | 2013 | 13 | 0.100 |
Why?
| | Valsartan | 1 | 2013 | 32 | 0.100 |
Why?
| | Ambulatory Care | 2 | 2023 | 609 | 0.100 |
Why?
| | Linear Models | 1 | 2016 | 845 | 0.100 |
Why?
| | Formularies as Topic | 2 | 2003 | 3 | 0.100 |
Why?
| | Biphenyl Compounds | 1 | 2013 | 67 | 0.100 |
Why?
| | Valine | 1 | 2013 | 83 | 0.100 |
Why?
| | Drug Substitution | 1 | 2013 | 63 | 0.100 |
Why?
| | Biomarkers | 1 | 2024 | 4295 | 0.090 |
Why?
| | Contraindications | 1 | 2012 | 90 | 0.090 |
Why?
| | Gemfibrozil | 1 | 2012 | 9 | 0.090 |
Why?
| | Population Surveillance | 1 | 2016 | 484 | 0.090 |
Why?
| | Simvastatin | 1 | 2012 | 59 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2025 | 2664 | 0.090 |
Why?
| | Hypolipidemic Agents | 1 | 2012 | 89 | 0.090 |
Why?
| | Costs and Cost Analysis | 1 | 2012 | 221 | 0.090 |
Why?
| | Mitoxantrone | 1 | 2011 | 15 | 0.090 |
Why?
| | Glatiramer Acetate | 1 | 2011 | 18 | 0.090 |
Why?
| | Age Distribution | 1 | 2012 | 403 | 0.090 |
Why?
| | Hematologic Tests | 1 | 2011 | 22 | 0.080 |
Why?
| | United States Food and Drug Administration | 1 | 2012 | 208 | 0.080 |
Why?
| | Colorado | 3 | 2024 | 4553 | 0.080 |
Why?
| | Prevalence | 3 | 2024 | 2865 | 0.080 |
Why?
| | Financing, Personal | 1 | 2011 | 27 | 0.080 |
Why?
| | Interferon-beta | 1 | 2011 | 92 | 0.080 |
Why?
| | Poisson Distribution | 1 | 2010 | 78 | 0.080 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 96 | 0.080 |
Why?
| | Likelihood Functions | 1 | 2010 | 138 | 0.080 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2017 | 668 | 0.080 |
Why?
| | Spine | 1 | 2011 | 182 | 0.080 |
Why?
| | Length of Stay | 1 | 2016 | 1349 | 0.080 |
Why?
| | Analysis of Variance | 1 | 2012 | 1300 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2017 | 2930 | 0.070 |
Why?
| | Preferred Provider Organizations | 1 | 2009 | 3 | 0.070 |
Why?
| | Quality-Adjusted Life Years | 2 | 2024 | 123 | 0.070 |
Why?
| | Respiratory Function Tests | 1 | 2011 | 544 | 0.070 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 1044 | 0.070 |
Why?
| | Patient Discharge | 1 | 2016 | 992 | 0.070 |
Why?
| | Private Sector | 1 | 2009 | 50 | 0.070 |
Why?
| | Orthopedic Procedures | 1 | 2011 | 244 | 0.070 |
Why?
| | Transportation | 1 | 2009 | 57 | 0.070 |
Why?
| | Treatment Outcome | 2 | 2014 | 11772 | 0.070 |
Why?
| | Regression Analysis | 2 | 2009 | 1001 | 0.070 |
Why?
| | North America | 1 | 2009 | 302 | 0.070 |
Why?
| | Pain Management | 1 | 2011 | 410 | 0.070 |
Why?
| | Electrocardiography | 1 | 2011 | 665 | 0.070 |
Why?
| | Incidence | 2 | 2024 | 2923 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2012 | 1217 | 0.070 |
Why?
| | Research Design | 1 | 2014 | 1137 | 0.060 |
Why?
| | Proportional Hazards Models | 1 | 2011 | 1327 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 6066 | 0.060 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1547 | 0.060 |
Why?
| | Electronic Health Records | 1 | 2014 | 1196 | 0.060 |
Why?
| | Program Evaluation | 1 | 2010 | 943 | 0.060 |
Why?
| | Patient Acceptance of Health Care | 1 | 2012 | 881 | 0.060 |
Why?
| | Peptides | 1 | 2011 | 998 | 0.060 |
Why?
| | Logistic Models | 1 | 2010 | 2134 | 0.060 |
Why?
| | Anti-Allergic Agents | 1 | 2005 | 40 | 0.050 |
Why?
| | Time Factors | 1 | 2016 | 7123 | 0.050 |
Why?
| | Efficiency, Organizational | 1 | 2005 | 141 | 0.050 |
Why?
| | Benchmarking | 1 | 2005 | 191 | 0.050 |
Why?
| | Comparative Effectiveness Research | 1 | 2025 | 168 | 0.050 |
Why?
| | Follow-Up Studies | 1 | 2013 | 5423 | 0.050 |
Why?
| | Histamine H2 Antagonists | 1 | 2004 | 23 | 0.050 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 360 | 0.050 |
Why?
| | Neuroglia | 1 | 2024 | 173 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2953 | 0.050 |
Why?
| | Hyperlipidemias | 1 | 2003 | 120 | 0.050 |
Why?
| | Patient Compliance | 2 | 2003 | 587 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2005 | 740 | 0.040 |
Why?
| | Pamphlets | 1 | 2001 | 26 | 0.040 |
Why?
| | Health Care Surveys | 1 | 2023 | 536 | 0.040 |
Why?
| | Decision Making | 2 | 2015 | 977 | 0.040 |
Why?
| | Hypoglycemic Agents | 1 | 2010 | 1399 | 0.040 |
Why?
| | Risk Assessment | 1 | 2010 | 3747 | 0.040 |
Why?
| | Students, Pharmacy | 1 | 2001 | 96 | 0.040 |
Why?
| | Hospitalization | 1 | 2009 | 2460 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3904 | 0.030 |
Why?
| | Child | 3 | 2024 | 22707 | 0.030 |
Why?
| | Models, Econometric | 1 | 2017 | 34 | 0.030 |
Why?
| | Recurrence | 1 | 2020 | 1138 | 0.030 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2014 | 3922 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2024 | 3623 | 0.030 |
Why?
| | Neurons | 1 | 2024 | 1649 | 0.030 |
Why?
| | Registries | 1 | 2023 | 2406 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2017 | 765 | 0.020 |
Why?
| | Medical Audit | 1 | 2013 | 77 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1323 | 0.020 |
Why?
| | Diabetes Complications | 1 | 2014 | 224 | 0.020 |
Why?
| | Pandemics | 1 | 2020 | 1707 | 0.020 |
Why?
| | Sex Factors | 1 | 2017 | 2105 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 2015 | 477 | 0.020 |
Why?
| | Databases, Factual | 1 | 2016 | 1490 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 3342 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2015 | 1747 | 0.020 |
Why?
| | Comorbidity | 1 | 2014 | 1661 | 0.020 |
Why?
| | Rhinitis, Allergic, Perennial | 1 | 2005 | 20 | 0.010 |
Why?
| | California | 1 | 2005 | 471 | 0.010 |
Why?
| | Coronary Disease | 1 | 2003 | 381 | 0.010 |
Why?
| | Child, Preschool | 1 | 2016 | 11853 | 0.010 |
Why?
| | Risk Factors | 1 | 2003 | 10885 | 0.000 |
Why?
|
|
Nair's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|